What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AbbVie, Immunome Enter Antibody Alliance

Multi-year collaboration aims to identify up to 10 novel target-antibody pairs using Immunome's Discovery Engine.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Immunome, Inc., a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to develop first-in-class antibody therapeutics, have entered a worldwide collaboration and option agreement to discover up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine.
 
Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from the selected tumors. Immunome will $30 million upfront and is eligible to receive additional platform access payments totaling as much as $70 million based on AbbVie’s election for Immunome to continue research using its Discovery Engine. 
 
Immunome is also eligible to receive development and first commercial sale milestones of as much as $120 million per target for certain products derived from target-antibody pairs that AbbVie elects to purchase, with potential for further sales-based milestones and royalties.

“Partnering with Immunome represents AbbVie’s commitment to developing and commercializing novel treatment approaches for solid tumors,” said Steve Davidsen, Ph.D., vice president, oncology discovery research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates. We look forward to utilizing their Discovery Engine to enhance our existing oncology pipeline.”
 
Purnanand Sarma, Ph.D., president and CEO of Immunome said, “AbbVie shares our vision of harnessing the power of the human immune response to yield novel and first-in-class therapeutics that represent a shift in the cancer discovery paradigm. We are delighted to be working with AbbVie and look forward to leveraging their vast development and commercialization expertise in bringing new therapies to patients suffering from life-threatening cancers. This collaboration fits well within Immunome’s strategy to maximize the new drug discovery potential of our Discovery Engine through partnerships across multiple therapeutic segments, in addition to advancing our own proprietary pipeline.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics